Study overview.

Schematic representing the experimental pipeline of an advanced in vitro human vascular surrogate model to create a response database from FDA-regulated compounds. Computational biology tools identified pharmacological classifiers that predicted cardiovascular risk. This database was applied to xanthine oxidase (XO) inhibitors, such as febuxostat, to explore responses and provide context to apparently contradictory clinical trial results.